Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy after confirming non-resistance to aspirin. &nbsp;Primary end point was a combination of death, infarction, emergency revascularization of target vessel, stroke and major bleeding. The study saw early termination due to<a href="https://solaci.org/en/2015/06/24/italic-plus-6-months-of-double-antiaggregation-for-no-less-than-24-months/" title="Read more" >...</a>

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination of anticoagulants, aspirin, and clopidogrel greatly increases the rate of bleeding, because of this, the time of the triple scheme should be as short as possible.&nbsp; The aim of this study was to compare the triple therapy for<a href="https://solaci.org/en/2015/06/24/isar-triple-6-weeks-versus-6-months-of-clopidogrel-in-patients-with-oral-anticoagulation-and-drug-eluting-stent/" title="Read more" >...</a>

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the treatment of multiple recurrences.&nbsp; 240patients were randomized to colchicine plus conventional anti-inflammatory scheme (aspirin, ibuprofen or indomethacin). The primary endpoint was the rate of recurrence of pericarditis in 18 months. The<a href="https://solaci.org/en/2015/06/24/corp-2-trial-colchicine-effective-in-reducing-the-recurrence-of-pericarditis-associated-withconventional-anti-inflammatory-pattern/" title="Read more" >...</a>

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing cardiovascular events in patients with chronic ischemic heart disease.Lp-PLA2 is an enzyme found in the blood andatherosclerotic plaques and high levels are associated with an increased risk of cardiovascular events.Direct inhibition of this enzyme with proinflammatory Daraplabid may<a href="https://solaci.org/en/2015/06/24/stability-trial-daraplabid-no-benefits-in-chronic-coronary-artery-disease/" title="Read more" >...</a>

A multicenter randomized study, (n = 573), that evaluated the role of aspirin in anticoagulated patients undergoing angioplasty. The primary endpoint was the rate of total bleeding, (TIMI), at 12 months follow-up. The administration of a dual therapy, (warfarin + clopidogrel), showed a significant reduction compared with the triple therapy, (19.5% vs. 44.9%, P &lt;0.001).<a href="https://solaci.org/en/2015/06/24/woest-randomized-trial-that-compared-dual-therapy-versus-triple-therapy-on-anticoagulated-patients/" title="Read more" >...</a>

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel versus aspirin + prasugrel in patients admitted with acute coronary syndromes without ST-segment elevation and initially treated with a conservative strategy. The study concluded that the administration of prasugrel did not<a href="https://solaci.org/en/2015/06/24/trilogy-trial-first-large-scale-test-evaluating-platelet-function-in-acute-coronary-syndromes/" title="Read more" >...</a>

A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients from 28 sites in India and Europe with an event risk higher than 15% at 5 years of conventional therapy or a polypill which combined aspirin, statin, lisinopril and atenolol/hydrochlorothiazide in fixed doses. At a 24 month follow<a href="https://solaci.org/en/2015/06/24/umpire-trial-the-polypill-proves-effective-in-treating-high-risk-patients/" title="Read more" >...</a>

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of bedside platelet function monitoring with drug adjustment vs. the conventional post DES therapy without monitoring and drug adjustment. It included 2466 patients with stable coronary disease or Non-ST Elevation<a href="https://solaci.org/en/2015/06/24/artic-study-bedside-platelet-function-monitoring-to-reduce-events-after-des-implantation/" title="Read more" >...</a>

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained unanswered: What is the utility of starting the infusion during the ambulance journey? Is it possible to reduce the risk of acute thrombosis by extending bivalirudin infusion or<a href="https://solaci.org/en/2015/06/24/euromax-bivalirudin-during-transport-to-primary-angioplasty/" title="Read more" >...</a>

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 &#8211; months versus 12 months of dual antiplatelet&nbsp; after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to<a href="https://solaci.org/en/2015/06/24/optimize-3-versus-12-months-dual-antiplatelet-therapy-after-angioplasty-with-des/" title="Read more" >...</a>